A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)



Status:Completed
Conditions:Renal Impairment / Chronic Kidney Disease
Therapuetic Areas:Nephrology / Urology
Healthy:No
Age Range:18 - 80
Updated:4/21/2016
Start Date:February 2013
End Date:August 2013

Use our guide to learn which trials are right for you!

A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia

The purpose of this study was to evaluate the efficacy and safety of patiromer
(investigational drug) in the treatment of hyperkalemia (high serum potassium). The study
also evaluated the effect of withdrawing patiromer treatment and assessed whether chronic
treatment with patiromer prevented the recurrence of hyperkalemia. The safety of patiromer
treatment was also evaluated.

There were two parts in the study, Part A and Part B.

Part A was an assessment of 4 weeks of dosing with patiromer in the treatment of
hyperkalemia; Part B was a randomized, placebo-controlled, 8-week assessment of the
withdrawal of patiromer in participants with a baseline serum potassium at the beginning of
Part A ≥ 5.5 mEq/L who responded to the 4 weeks of treatment with patiromer during Part A.

All participants received patiromer during Part A; Part B participants were randomized to
continue patiromer or switch to placebo. Total study participation was up to 14 weeks
(including up to 2 weeks of follow up).

The dose of patiromer could be titrated based on participant's serum potassium response.

Inclusion Criteria:

- Males and females ages 18 - 80

- Chronic kidney disease (CKD) - eGFR 15 to < 60 mL/min/1.73m2 at screening

- Hyperkalemia, defined as a serum potassium value of 5.1 to < 6.5 mEq/L at screening

- Taking either an Angiotensin-Converting Enzyme (ACE) Inhibitor, an Angiotensin II
receptor blocker (ARB), or an aldosterone antagonist (AA) medication

- Informed consent given

Exclusion Criteria:

- Participants with auto-immune related chronic kidney disease such as lupus nephritis
or renal scleroderma/scleroderma renal crisis, or mixed connective tissue disease
with renal involvement

- Participants with uncontrolled Type 1 diabetes, defined as or a HbA1c > 10.0 %, or
hospitalization to treat hyper- or hypo-glycemia in the past 3 months within the
previous 6 months in participants with Type 2 diabetes

- Participants with severe heart failure, defined as NYHA (New York Heart Association)
class IV

- Participants with major surgery including thoracic and cardiac, in the past 3 months,
or participants with heart or kidney transplant

- Participants with significant cardiovascular or cerebrovascular events in the past 2
months, such as cardiac arrest, myocardial infarction, or stroke

- Participants with BMI ≥ 40 kg/m2
We found this trial at
15
sites
?
mi
from
Augusta, GA
Click here to add this to my saved trials
?
mi
from
Azusa, CA
Click here to add this to my saved trials
?
mi
from
Bethlehem, PA
Click here to add this to my saved trials
?
mi
from
Edgewater, FL
Click here to add this to my saved trials
?
mi
from
Farmington, MO
Click here to add this to my saved trials
?
mi
from
Flushing, NY
Click here to add this to my saved trials
?
mi
from
Hollywood, FL
Click here to add this to my saved trials
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
?
mi
from
Karlovac,
Click here to add this to my saved trials
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
Port Charlotte, FL
Click here to add this to my saved trials
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
Santa Barbara, California 93105
?
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
?
mi
from
Ventura, CA
Click here to add this to my saved trials